trial

The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation

NCTId NCT02935998
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 1,000 (estimated)
Sponsored by Yang Fude
Primary completion 2017-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
1,000 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-10
Primary completion
2017-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ziprasidone

Sponsors

Yang FudeLead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

1
Yang Fude, directorPrincipal Investigator

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
1,000
Phase
PHASE4
Primary Completion Date
2017-12
Status
UNKNOWN
relationships
The graph out of here
drug
Ziprasidone
drug
lead_sponsor
Yang Fude
company
collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Psychomotor Agitation
indication
Schizophrenia
indication
investigator
Yang Fude, director
person